Dr. Alexandre Bazinet, MD

Dr. Bazinet practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Bazinet's NPI, 1669045514, was assigned on July 19, 2021. Dr. Bazinet graduated from McGill University Faculty of Medicine in 2014. Dr. Bazinet holds Texas license 47986.

Dr. Bazinet's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Bazinet's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bazinet practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Bazinet's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Bazinet is board certified in internal medicine by the American Board of Internal Medicine. Dr. Bazinet is licensed in Texas.

CMS data shows 567 Medicare services from Dr. Bazinet across 5 procedure codes in 2024, for 98 Medicare patients. Medicare paid $55,600 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 98 Medicare patients who saw Dr. Bazinet in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have high blood pressure, and 71% have high cholesterol. Their average risk score is 3.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bazinet's median patient age at 71, with 44% women.

In 2024, Dr. Bazinet wrote 190 Medicare Part D claims for 59 patients. 77% of them were for generic drugs. CMS names the drug for 58 of them, across 3 drugs with 11 or more claims each, at $36,770 in total drug cost. In 2023, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Bazinet for performance year 2024, reported as part of a group. Dr. Bazinet accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 43 papers to Dr. Bazinet, published from 2019 to 2025. 2024 was the busiest year, with 11. The most frequent topics are Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic and Sulfonamides. Dr. Bazinet has published most often in Am J Hematol. Dr. Bazinet's most frequent co-authors are Tapan M. Kadia, MD, Naval Gustad Daver, MBBS and Courtney Denton Dinardo, MD.

CMS Open Payments shows 17 general payments to Dr. Bazinet from 10 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Celgene Corporation paid the most, $149.

Dr. Bazinet graduated from McGill University Faculty of Medicine in 2014.

Dr. Bazinet is in network with 3 carriers, including Aetna, Blue Cross Blue Shield of Michigan and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.